New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
11:22 EDTNVS, ACT, AGNAllergan Latisse patents found invalid by appeals court
The U.S. court of appeals for the federal circuit overturned a lower court ruling related to Allergan's (AGN) patents for Latisse, a treatment for eyelash loss. Several companies, including Actavis (ACT) and Novartis' (NVS) Sandoz unit, appealed a lower court ruling that said they'd infringed Allergan's patents. The appeals court sided with the appealing companies and reversed the district court's findings with respect to the validity of the patents held by Allergan and Duke University. Reference Link
News For AGN;ACT;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 17, 2014
09:34 EDTACT, AGNCombined Actavis-Allergan to be led by Actavis CEO Saunders
Actavis (ACT) and Allergan (AGN) said The combined company will be led by Brent Saunders, CEO and President of Actavis, and Paul Bisaro will remain Executive Chairman of the Board. The integration of the two companies will be led by the senior management teams of both companies, with integration planning to begin immediately in order to transition rapidly to a single company. Additionally, two members of the Allergan board of directors will be invited to join the Actavis Board of Directors following the completion of the transaction.
09:32 EDTACT, AGNValeant says cannot justify paying $219 per share for Allergan
Valeant Pharmaceuticals (VRX) commented on the announcement that Allergan (AGN) and Actavis (ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock: "We have seen the announcement that Allergan and Actavis have made, and while we will review any such agreement in determining our course of action, Valeant cannot justify to its own shareholders paying a price of $219 or more per share for Allergan. Our business is performing extremely well as evidenced by our third quarter results, our expected strong fourth quarter, and our robust outlook for 2015, and I am confident in our continued ability to generate exceptional shareholder value. We will remain focused on delivering strong organic results and evaluating acquisition opportunities as we always have: prudently, in a disciplined manner, and in the best interests of our shareholders."
09:29 EDTAGN, ACTActavis to host conference call
Conference call to discuss the acquisition of Allergan will be held on November 17 at 10:30 am. Webcast Link
09:24 EDTACT, AGNAllergan up over 5% to $209 after agreeing to be acquired by Actavis
Subscribe for More Information
09:22 EDTACTOn The Fly: Pre-market Movers
Subscribe for More Information
09:21 EDTACT, AGNActavis, Allergan transaction subject to approval of shareholders of both
Subscribe for More Information
09:20 EDTAGN, ACTActavis projects at least $1.8B in annual synergies from Allergan transaction
Subscribe for More Information
09:18 EDTACT, AGNActavis sees free cash flow over $8B in 2016 following Allergan acquisition
Subscribe for More Information
09:16 EDTACT, AGNActavis confirms deal to acquire Allergan for $219 in cash, stock
Subscribe for More Information
09:15 EDTACT, AGNActavis confirms deal to acquire Allergan for $219 in cash and shares
Subscribe for More Information
09:10 EDTACT, AGNActavis buying Allergan for $219 per share, CNBC reports
08:02 EDTACTActavis completes Durata Therapeutics tender offer
Subscribe for More Information
06:05 EDTAGN, ACTActavis close to buying Allergan for over $64B, Bloomberg reports
Subscribe for More Information
November 16, 2014
15:07 EDTNVSNovartis says arthritis drug secukinumab met primary endpoint
Subscribe for More Information
14:02 EDTACT, AGNAllergan, Actavis move closer to deal, WSJ reports
Subscribe for More Information
November 14, 2014
16:58 EDTACTThird Point gives quarterly update on stakes
NEW STAKES: Alibaba (BABA), eBay (EBAY), Bed Bath & Beyond (BBBY), Shire (SHPG), and Parker Hannifin (PH). INCREASED STAKES: Actavis (ACT), Amgen (AMGN), EQT (EQT), Sensata (ST), Coca-Cola Enterprises (CCE). DECREASED STAKES: Williams Cos (WMB), Ally Financial (ALLY), Cheniere Energy (LNG), YPF (YPF), and FedEx (FDX). LIQUIDATED STAKES: AIG (AIG), T-Mobile (TMUS), Rackspace (RAX), Hertz (HTZ), and Citrix Systems (CTXS).
14:53 EDTNVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:53 EDTACTOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
07:32 EDTACTHayman Capital gives quarterly update on stakes
Subscribe for More Information
07:14 EDTNVSAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use